| Date Filed | Type | Description |
| 08/10/2023 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 07/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/10/2023 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 05/02/2023 |
4
| STEEL PARTNERS HOLDINGS L.P. (10% Owner) has filed a Form 4 on Steel Connect, Inc.|
Txns:
| Granted 112,043 options to buy
@ $1.1, valued at
$123.2k
Granted 3,387,957 options to buy
@ $1.1, valued at
$3.7M
|
|
| 02/13/2023 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 11/15/2022 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 08/15/2022 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 05/11/2022 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 02/11/2022 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 11/16/2021 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 08/16/2021 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 05/14/2021 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 04/27/2021 |
GN
| Adaptive Biotechnologies to Present at the BofA Securities 2021 Virtual Healthcare Conference |
| 03/17/2021 |
GN
| Adaptive Biotechnologies Strengthens Expertise and Diversity of Board of Directors with Appointments of Leslie Trigg and Katey Owen |
| 03/05/2021 |
GN
| Adaptive Biotechnologies Announces FDA Emergency Use Authorization for T-Detect™ COVID to Confirm Recent or Prior COVID-19 Infection |
| 02/25/2021 |
GN
| Adaptive Biotechnologies to Present at the Cowen 41st Annual Healthcare Conference |
| 02/23/2021 |
GN
| Adaptive Biotechnologies Expands Collaboration with Labcorp to Increase Access to Growing Research and Clinical Diagnostic Portfolio |
| 02/23/2021 |
GN
| Adaptive Biotechnologies Launches T-Detect™ COVID, First Clinical T-Cell Based Test for Patients to Confirm Recent or Prior COVID-19 Infection |
| 02/12/2021 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 02/03/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 01/28/2021 |
SC 13D/A
| Steel Excel Inc. reports a 7.8% stake in Aviat Networks, Inc. |
| 01/27/2021 |
4
| Steel Excel Inc. (10% Owner) has filed a Form 4 on AVIAT NETWORKS, INC.|
Txns:
| Sold 31,787 shares
@ $37.8513, valued at
$1.2M
|
|
| 01/11/2021 |
GN
| Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics |
| 12/30/2020 |
GN
| Adaptive Biotechnologies to Present at the 39th Annual J.P. Morgan Healthcare Conference |
| 12/22/2020 |
SC 13D/A
| Steel Excel Inc. reports a 10.1% stake in Aviat Networks, Inc. |
| 12/21/2020 |
4
| Steel Excel Inc. (10% Owner) has filed a Form 4 on AVIAT NETWORKS, INC.|
Txns:
| Sold 464 shares
@ $37.9491, valued at
$17.6k
Sold 5,400 shares
@ $37.0002, valued at
$199.8k
|
|
| 12/17/2020 |
4
| Steel Excel Inc. (10% Owner) has filed a Form 4 on AVIAT NETWORKS, INC.|
Txns:
| Sold 35,100 shares
@ $37.3059, valued at
$1.3M
|
|
| 12/17/2020 |
SC 13D/A
| Steel Excel Inc. reports a 10.2% stake in Aviat Networks, Inc. |
| 12/16/2020 |
4
| Steel Excel Inc. (10% Owner) has filed a Form 4 on AVIAT NETWORKS, INC.|
Txns:
| Sold 27,159 shares
@ $37.5305, valued at
$1M
Sold 24,128 shares
@ $37.5086, valued at
$905k
|
|
| 12/14/2020 |
SC 13D/A
| Steel Excel Inc. reports a 11.3% stake in Aviat Networks, Inc. |
| 12/11/2020 |
4
| Steel Excel Inc. (10% Owner) has filed a Form 4 on AVIAT NETWORKS, INC.|
Txns:
| Sold 10,244 shares
@ $40.5022, valued at
$414.9k
Sold 14,000 shares
@ $38.0075, valued at
$532.1k
|
|
| 12/06/2020 |
GN
| Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers at the 62nd ASH Annual Meeting |
| 11/23/2020 |
GN
| Adaptive Biotechnologies and Collaborators to Present Data from More Than 35 Abstracts at ASH 2020 Highlighting Clinical Relevance of MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients |
|